blood CD34
þ cell count on the day of leukapheresis was 34/mL (range: 22-52) and the median CD34 þ cell dose achieved was 3.1 Â 10 6 CD34 þ cell/kg (range: 2.6-4.0). All 9 patients underwent auto-SCT using either BEAM (n ¼ 6) or CBV (n ¼ 3) conditioning. The median time to neutrophil engraftment (ANC40.5 Â 10 9 /L) was 11 days (range: 10-17) and to platelet engraftment (platelet count4 20 Â 10 9 /L) was 18 days (range: 10-31). Following transplant, the overall response rate was 77.7%, with 5 (55.6%) showing a CR, 2 (22.2%) maintaining a PR and 2 (22.2%) with stable disease. At a median follow-up of 18 months (range: 7-45), 8 (80%) were alive, with 5 (50%) in CR. The use of pegfilgrastim in combination with an outpatientfractionated protocol of ICE salvage chemotherapy is well tolerated, with reasonable remission rates, although PBSC mobilization seems to be inferior to that associated with filgrastim.
A number of reports have confirmed the efficacy of pegfilgrastim when combined with ifosfamide-or platinumbased salvage chemotherapy in successful mobilization of PBSCs in patients with relapsed lymphoma. [6] [7] [8] [9] However, mobilization of PBSCs using chemotherapy and growth factors is subject to considerable inter-individual variation. In our series, three patients demonstrated very low CD34 þ cell numbers in the peripheral blood and were not leukapheresed. There is no unifying explanation for the failure to mobilize PBSCs; however, in one patient the white cell count rose to 26.9 Â 10 9 /L on day 8 of ICE therapy. Accordingly, one possible contributing factor to at least one of the mobilization failures relates to the timing of the pegfilgrastim in relation to the fractionated ICE chemotherapy and the early neutrophil-mediated clearance of pegfilgrastim. In a recent randomized study of pegfilgrastim, given on either day 2 or day 4 following CHOPlike chemotherapy, in which the cohort that received day-4 pegfilgrastim had statistically significantly fewer episodes of grade III/IV neutropenia, a more attenuated neutrophil nadir and higher serum levels of pegfilgrastim, it was proposed that as the neutrophil-mediated clearance is the major route of pegfilgrastim elimination, deferring the administration of pegfilgrastim until the neutrophils start to fall should result in a reduced clearance with consecutively higher pegfilgrastim serum levels during the nadir. 10 Similarly, it is possible that such an effect on clearance of pegfilgrastim may be operative in the setting of other intermediate-intensity chemotherapy regimens, such as ICE or DHAP, used for relapsed/refractory lymphomas. As delaying the administration of pegfilgrastim beyond day 4 may increase the serum levels of pegfilgrastim, we are in the
